Lynn Schuchter: Thoroughly looking forward to this ASCO24 joint session with AACR, ‘Drugging the ‘Undruggable’ Target

Lynn Schuchter shared a post by ASCO on X, adding:

“Thoroughly looking forward to this ASCO24 joint session with AACR, ‘Drugging the ‘Undruggable’ Target: Successes, Challenges, and the Road Ahead.’”

Quoting ASCO’s post:

“At ASCO24, a joint session w/ AACR will bring together academia & pharma experts to discuss new advances & the science of targeting the ‘undruggable’ drivers of cancer.”

Read further.
Source: Lynn Schuchter/X and ASCO/X

Lynn M. Schuchter is the President of the American Society of Clinical Oncology (ASCO). Dr. Schuchter is the Chief of the Division of Hematology-Oncology at the Abramson Cancer Center at the University of Pennsylvania, Director of the Tara Miller Melanoma Center and Professor of Hematology-Oncology at the Perelman School of Medicine at the University of Pennsylvania.

Dr. Schuchter served on the ASCO Board of Directors from 2009 to 2012, as well as several ASCO committees, including terms as Chair of the Annual Meeting Scientific Program Committee, Cancer Research Committee, and Cancer Communications Committee. In 2019, she was awarded ASCO’s Women Who Conquer Cancer Mentorship Award.

The American Society of Clinical Oncology (ASCO) is a leading professional organization representing nearly 45,000 physicians and oncology specialists worldwide, dedicated to cancer care. Founded in 1964 by Fred Ansfield, Harry Bisel, Herman Freckman, Arnoldus Goudsmit, Robert Talley, William Wilson, and Jane C. Wright, ASCO is committed to advancing cancer research, education, prevention, and high-quality patient care..